ArticleRSC advances2026
Formulation-dependent colloidal properties of redispersible lycopene nanoparticles: storage stability and enhanced
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lycopene is a bioactive carotenoid whose application is limited by poor aqueous dispersibility and susceptibility to degradation. Redispersible lycopene nanoparticles were prepared by solvent displacement-evaporation followed by freeze-drying, and interfacial composition and nominal lycopene fraction were evaluated sequentially. Among the tested interfacial compositions, a 2 : 1 Tween 80/phosphatidylcholine mass ratio produced the smallest particles and lowest dispersity. At this ratio, the formulation containing 12 wt% nominal lycopene was selected for its balance of lycopene content, particle size, and dispersity. The measured lycopene content of the freeze-dried formulation was 11.63 wt%; after aqueous redispersion, the particles exhibited a mean hydrodynamic diameter of 133.25 ± 1.46 nm, a polydispersity index of 0.173 ± 0.016, and a zeta potential of -38.3 ± 1.9 mV. TEM showed predominantly near-spherical particles. FTIR spectra were consistent with physical incorporation in the matrix, while XRD showed marked attenuation of crystalline lycopene reflections. The redispersed formulation maintained its colloidal characteristics for 7 days at 4 °C, and the freeze-dried formulation retained 91.9% of its initial lycopene content after 180 days at -20 °C. At matched lycopene doses, the formulation showed higher apparent DPPH radical-scavenging activity and greater protection against H
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.